National Comprehensive Cancer Network

|
|
|
|
For Patients
About the NCCN Clinical Practice Guidelines in Oncology™
Recent Updates to NCCN Clinical Practice Guidelines in Oncology™
NCCN Categories of Evidence and Consensus
NCCN Guidelines Steering Committee
Submission Request to the NCCN Guidelines Panels
NCCN Guidelines Panels-Meeting Schedule
NCCN Drugs & Biologics Compendium™
About the NCCN Drugs & Biologics Compendium™
Compendium Chapters
No Longer Recommended Uses
JNCCN – The Journal of the National Comprehensive Cancer Network
Subscribe Now
FAQ
JNCCN Task Force Supplements

Clinical Recommendations

NCCN 2nd Annual Congress Hematologic Malignancies

Clinicians

Register Online

Congress Information

Program Overview

Educational Objectives

Conference Agenda

Intended Audience

Accreditation

Accommodations

Commercial Support

Exhibiting

Refer a Friend


Go back to previous page

 

 

     
 

NCCN 2nd Annual Congress:
Hematologic Malignancies™
Agenda

* Note: Agenda, presenters, and specific session times are subject to change.


Friday, September 14, 2007

7:30 – 8:45 AM

Registration, Breakfast, and Exhibits

8:45 – 8:50 AM

Welcome

Multiple Myeloma

8:55 – 9:30 AM

The Emerging Role of Novel Therapies in Initial and Subsequent Lines of Treatment
Paul G. Richardson, MD
Dana-Farber/Brigham and Women`s Cancer Center | Massachusetts General Hospital Cancer Center

9:35 – 10:05 AM

How to Treat Patients that Progress or Relapse
Seema Singhal, MD
Robert H. Lurie Comprehensive Cancer Center of
Northwestern University

10:05 – 10:25 AM

Break and Exhibits

10:25 – 10:55 AM

Treatment of Systemic Light Chain Amyloidosis
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center

Acute Myeloid Leukemia (AML)

11:00 AM – 12:00 PM

Treatment of Acute Myeloid Leukemia
Harry P. Erba, MD, PhD
University of Michigan Comprehensive Cancer Center

12:00 – 12:45 PM

Lunch and Exhibits

Non-Hodgkin’s Lymphoma (NHL)

12:45 – 1:30 PM

Cutaneous T-Cell Lymphomas
Youn H. Kim, MD
Stanford Comprehensive Cancer Center

Chronic Myelogenous Leukemia (CML)

1:35 – 2:05 PM

Update on Primary Therapy, Second-Line
Therapy, and New Agents
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

2:05 – 2:25 PM

Break

Myelodysplastic Syndromes (MDS)

2:25 – 3:10 PM

Implications of the 2008 WHO Reclassification
John M. Bennett, MD
University of Rochester Medical Center

3:15 – 3:35 PM

Treatment by Risk Groups
Harry P. Erba, MD, PhD
University of Michigan Comprehensive Cancer Center

3:40 – 4:00 PM

Who Would Benefit From Immunosuppressive Therapy?
Maria R. Baer, MD
The University of Maryland Greenebaum Cancer Center

4:00 – 5:30 PM

Reception


Saturday September 15, 2007

7:30 – 8:00 AM

Registration and Breakfast

Non-Hodgkin’s Lymphoma (NHL)

8:00 – 8:30 AM

Low-Grade Lymphomas
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center

8:35 – 9:05 AM

Mantle Cell Lymphoma
Myron S. Czuczman, MD
Roswell Park Cancer Institute

Supportive Care for Patients with Hematologic Malignancies

9:10 – 9:40 AM

Transfusion Support and Iron Overload in MDS
Stephen D. Nimer, MD
Memorial Sloan-Kettering Cancer Center

9:45 – 10:15 AM

Blood Products and Growth Factors in the
Treatment of Thrombocytopenia
Farhad Ravandi, MD                  
The University of Texas M. D. Anderson Cancer Center

10:15 – 10:40 AM

Break

10:40 – 11:10 AM

Tumor Lysis Syndrome
David J. Straus, MD
Memorial Sloan-Kettering Cancer Center

11:15 – 11:45 AM

Skeletal Complications
Kenneth C. Anderson, MD
Dana-Farber/Brigham and Women`s Cancer Center | Massachusetts General Hospital Cancer Center

11:45 AM – 12:15 PM

Managing Infections in Patients with Hematologic Malignancies
Brahm Segal, MD
Roswell Park Cancer Institute

12:20 PM

Closing Remarks